EDMONTON, Alberta, July 5, 2012 (GLOBE NEWSWIRE) -- Isotechnika Pharma
Inc. (TSX:ISA) ("Isotechnika" or the "Company") announced today that
its CEO, Dr. Robert Foster, will present an update on the Company's
business at the Seventh Annual JMP Securities Healthcare Conference in
New York City on Thursday, July 12, 2012 at 4:30pm ET.
About Isotechnika Pharma Inc.
Isotechnika Pharma Inc. is a biopharmaceutical company focused on the
discovery and development of immunomodulating therapeutics designed to
offer key safety advantages over currently available treatments. Its
lead drug, voclosporin, is a calcineurin inhibitor, and is targeted at
the estimated US$3.0 billion market for this class of
immunosuppressants. Isotechnika Pharma Inc. trades on the Toronto Stock
Exchange under the symbol "ISA". More information on Isotechnika Pharma
can be found at www.isotechnika.com or www.sedar.com.
We seek Safe Harbour.
CONTACT: Dr. Robert Foster
Chairman & CEO
Dr. Launa Aspeslet
Chief Operating Officer
Kilmer Lucas Inc.